Abstract
Background Isolated REM sleep behavior disorder (iRBD) is known to be an early feature in some PD patients. Quantitative tools are needed to detect early motor anomalies in iRBD.
Methods A motor battery was used to compare iRBD patients with controls. This included two online keyboard-based tests, the BRadykineisa Akinesia INcoordination (BRAIN) test and the Distal Finger Tapping (DFT) test, a timed handwriting task and two motor assessments (10-meter walking and finger tapping) carried out both alone and during a mental task. This battery was compared with the motor section of the MDS-MDS-UPDRS-III. ROC analyses were used to measure diagnostic accuracy.
Results We included 33 patients with video-PSG-confirmed iRBD and 29 age and sex matched controls. The iRBD group performed the BRAIN test and DFT test more slowly (p<0.001, p=0.020 respectively) and erratically (p<0.001, p=0.009 respectively) than controls. Handwriting speed was 10 seconds slower in iRBDs than controls (p=0.004). Unlike controls, under a mental task the iRBD group decreased their walking pace (p<0.001) and had a smaller amplitude (p=0.001) and slower (p=0.007) finger tapping than tasks in isolation. The combination of BRAIN & DFT tests with the effect of mental tasks on walking and finger tapping showed 90.3% sensitivity for 89.3% specificity (AUC 0.94, 95% CI 0.88-0.99), which was higher than the MDS-UPDRS-III (minus action tremor) (69.7% sensitivity, 72.4% specificity; AUC 0.81, 95% CI 0.71-0.91) for detecting motor abnormalities.
Conclusion This study suggests that speed, incoordination, and dual task motor deterioration might be accurate indicators of incipient PD in iRBD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was granted by the Queen Square Research Ethics Committee (09/H0716/48). Participants received verbal and written information about the study and appropriately consented to take part in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial Disclosures: The PREDICT-PD study is funded by Parkinson’s UK. The Preventive Neurology Unit is funded by the Barts Charity.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
